---
title: 'Software Daily Summary: What Happened on October 26, 2026'
headline: Lunit and Summit to assess AI pathology platform in ivonescimab research
description: The planned analysis will look for biomarkers and group patients, but
  the agreement excludes clinical outcome data.
url: https://thebench.bio/news/software/2026-10-26
topic: software
date: '2026-10-26'
covers:
- '2026-10-26'
date_published: '2026-10-26T12:05:18Z'
date_modified: '2026-10-26T12:05:18Z'
tags:
- Industry
sources: 1
publisher: TheBench.Bio
---

# Software Daily Summary: What Happened on October 26, 2026

**Lunit and Summit to assess AI pathology platform in ivonescimab research**

The planned analysis will look for biomarkers and group patients, but the agreement excludes clinical outcome data.

## Today in brief

Lunit and Summit plan to use AI analysis of tumor slides to study biomarkers and patient groups in ivonescimab research. [1]

## Also published

- [AI Twins Are Growing in the Pharma Industry](<https://www.pharmexec.com/view/ai-twins-growing-industry>), Pharmaceutical Executive

## Sources

1. [Lunit and Summit to evaluate pathology platform for tumour analysis](<https://www.pharmaceutical-technology.com/news/lunit-summit-pathology-platform-tumour-analysis/>), Pharmaceutical Technology, 2026-10-26

---

TheBench.Bio wrote this from the reporting cited above, with a language model drafting and editing.

[1]: <https://www.pharmaceutical-technology.com/news/lunit-summit-pathology-platform-tumour-analysis/>